本帖最后由 老马 于 2012-1-13 21:20 编辑 3 W# W0 N: b' Q" F) A
! @( k) q9 \ ~4 \
爱必妥和阿瓦斯丁的比较
8 [9 g5 x+ ~6 A) j/ ], e
1 T$ X R* ?8 h4 T* `) L
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
2 W" ]5 y- @" r* W$ v
8 K* d9 {( ?+ a/ a. L; z8 H' i! Q" r
0 f7 x- Q0 i$ V; P- L0 v0 hhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
. D9 L' k p x/ I4 j: l/ e2 h$ |==================================================
! D3 O8 n ?8 NOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)' U' N: F& I; r4 e V+ I& g% Z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.; F; z& V) Q5 R! I+ N
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
/ v: V) \% b) `
|